14,000 Shares in Abivax SA Sponsored ADR $ABVX Bought by Bamco Inc. NY

Bamco Inc. NY acquired a new stake in Abivax SA Sponsored ADR (NASDAQ:ABVX) in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 14,000 shares of the company’s stock, valued at approximately $1,189,000.

Several other large investors have also recently made changes to their positions in ABVX. EverSource Wealth Advisors LLC boosted its stake in Abivax by 4,612.5% in the third quarter. EverSource Wealth Advisors LLC now owns 377 shares of the company’s stock valued at $32,000 after acquiring an additional 369 shares during the last quarter. First Horizon Corp bought a new position in shares of Abivax during the 3rd quarter valued at approximately $36,000. Bank of America Corp DE increased its stake in shares of Abivax by 56.1% during the 4th quarter. Bank of America Corp DE now owns 5,536 shares of the company’s stock worth $41,000 after purchasing an additional 1,990 shares during the last quarter. Hantz Financial Services Inc. bought a new stake in shares of Abivax in the 3rd quarter worth approximately $52,000. Finally, Cubist Systematic Strategies LLC raised its holdings in shares of Abivax by 34.3% in the 1st quarter. Cubist Systematic Strategies LLC now owns 10,152 shares of the company’s stock worth $63,000 after purchasing an additional 2,595 shares during the period. 47.91% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on ABVX shares. Jefferies Financial Group started coverage on Abivax in a report on Monday. They set a “buy” rating and a $160.00 price objective for the company. Guggenheim restated a “buy” rating and issued a $175.00 target price on shares of Abivax in a research note on Thursday, December 18th. Wall Street Zen cut Abivax from a “hold” rating to a “sell” rating in a research report on Saturday, December 13th. BTIG Research reiterated a “buy” rating and set a $150.00 price target on shares of Abivax in a research note on Wednesday, February 25th. Finally, Piper Sandler reissued an “overweight” rating and issued a $142.00 price objective on shares of Abivax in a report on Tuesday, December 16th. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $136.69.

Abivax Stock Up 6.3%

ABVX opened at $122.75 on Tuesday. Abivax SA Sponsored ADR has a 12 month low of $4.77 and a 12 month high of $148.83. The company has a market cap of $9.71 billion, a PE ratio of -29.37 and a beta of 1.01. The company has a current ratio of 7.86, a quick ratio of 7.86 and a debt-to-equity ratio of 0.03. The company has a 50 day moving average of $118.98 and a 200 day moving average of $109.39.

Abivax (NASDAQ:ABVX) last issued its earnings results on Monday, December 15th. The company reported ($2.46) earnings per share (EPS) for the quarter. The business had revenue of ($4.92) million for the quarter. On average, sell-side analysts expect that Abivax SA Sponsored ADR will post -2.83 EPS for the current year.

Abivax Profile

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.